Ozempic, Mounjaro, Wegovy, or Zepbound? This ETF Holds Them All

GLP-1 injection pen, pills and vial on desk with stock charts behind, signaling weight-loss drug boom. Key Points With the FDA approval of GLP-1 agonists in pill form, the healthcare industry is looking to build on last year's momentum. Grand View Research forecasts the GLP-1 drug market to grow by a CAGR of nearly 19% through 2030. The Roundhill GLP-1 & Weight Loss ETF, which has gained 52% over the past year, provides a basket of leading companies involved in the manufacturing and sales of weight-los ...